FDA OKs emergency use of Illumina’s COVID-19 diagnostic test

The FDA has issued an Emergency Use Authorization for Illumina’s (NASDAQ:ILMN) COVIDSeq Test, a sequencing-based, in vitro diagnostic workflow enabling the detection of SARS-CoV-2.

The end-to-end workflow extends the options available for labs to scale diagnostic testing.

COVIDSeq uses upper respiratory specimens and delivers sample receipt to result in 24 hours using the NovaSeq 6000 Sequencing System.

The test currently has limited availability and is expected to be more broadly available this summer.

https://seekingalpha.com/news/3581810-fda-oks-emergency-use-of-illuminas-covidminus-19-diagnostic-test